Advanced Lab Research
Engineered to solve the complex
#1 ranking CRO*
Deep lab expertise meets LensAI™ insight—working with you as a strategic scientific thought partner to help uncover candidates with strong potential.
* ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Harder targets,
stronger starts.
Our biologics discovery process is front-loaded for workflow efficiency. By combining target-informed immunization, rigorous analysis, AI-enabled insights, and deep expertise, we generate diverse, phenotypically relevant antibody panels. This integrated approach brings developability and risk considerations forward—supporting more informed candidate selection and smoother downstream development.
Impact
35+ years
Decades of experience, high client retention
Discovery
>98% success*
Leading B-cell technology for advanced antibody discovery
*“Success” refers to meeting predefined discovery criteria, not clinical or therapeutic outcomes. Results may vary.
Track record
15+ molecules
Contributed to over 15 programs advancing to the clinic
Transformation
Innovation
Continuously advancing R&D and LensAI to meet evolving discovery needs
Transforming workflows
Comprehensive continuum
Front-loading discovery integrates diverse strategies and biological and computational insight from the start to support hit-to-lead progression. With AI-enabled analysis available from the earliest stages, this continuum is designed to support evidence-based candidate evaluation as programs move into downstream development.
Workflows designed to support candidate progression
Early-stage insights bring biological context forward, helping teams identify promising antibodies and make more informed development decisions.
Research highlights & innovation news
Used by teams across 19 of the top 20 global pharma companies, next-generation biotechs, and leading research institutions
3,000+ completed partner programs
across therapeutic, diagnostic and anti-drug antibody discovery
Advanced lab. Connected intelligence.
Next-gen drug discovery
Led by experts across science and technology, our lab combines depth, precision, and versatility to advance discovery. Integrated with the LensAI Bio-Native Intelligence Suite, it unites data and experimentation to evolve insight and help accelerate progress through development.
Antibody discovery and development
As a global leader in antibody discovery, we deliver state-of-the-art research that supports programs from exploration through downstream development. Our platforms are recognized for diversity and reproducibility, helping teams move promising candidates forward.
Antibody discovery with LensAI
B cell Select
Identify top antibodies early with function-first screening of target-enriched B cells. Multi-species versatility, high efficiency and exceptional hit-rate, native pair identification and AI-driven analysis make it especially powerful for challenging programs. With a demonstrated >98% success rate, B cell Select has advanced multiple candidates to the clinic.
Antibody discovery with LensAI
Hybridoma
Discover top antibodies in just two weeks with MindWalk’s single-step Hybridoma platform, leveraging semi-solid media and direct colony picking. Function-first screening, target-agnostic design, and the ability to accommodate challenging functional assays support the rapid identification of high-value clones across all targets.
Antibody discovery with LensAI
Yeast Display
Yeast display is a highly effective platform for screening antibody libraries from immune sources as well as for engineering of pre-existing clones. The fidelity of expression in the eukaryotic system combined with the affinity selection by FACS enables rapid enrichment and selection of clones with the most desirable properties.
Antibody Development with LensAI
Lead Characterization
Newly discovered antibody hits are systematically analyzed across structural, functional, and developability dimensions—including structural, functional, liability, immunogenicity, and paratope profiles—using integrated computational and experimental approaches to identify the most clinic-ready clones early in discovery.
Antibody Development with LensAI
Lead Optimization
Powered by the LensAI platform and HYFT® technology, our lead optimization integrates AI-guided rational design with wet-lab validation and simultaneous multi-feature analysis. The result is designed to deliver faster, data-driven refinement that minimizes trial-and-error, reduces early risk, and produces optimized leads with stronger performance and lower late-stage attrition.
Antibody Development with LensAI
Candidate Selection
MindWalk’s AI platform delivers smarter and faster discovery and development processes to achieve candidate selection with the highest confidence.
Emerging discovery modalities
MindWalk’s AI-driven discovery workflows span peptides, vaccines, and cell therapies, with lab research providing the experimental depth to validate insights and support programs addressing areas of unmet medical need.
LensAI Bio-Native Suite
HYFT Base™
Data and Insights Foundation
HYFT Base is the strategic foundation of biological intelligence, connecting sequence, structure, and literature to transform data into actionable insights. It supports informed strategies for target identification, validation, and discovery.
HYFT Matrix™
Exploration Layer
Integrating sequence, structure, function, and literature, HYFT Matrix reveals hidden relationships across data to help guide smarter selection and potentially lower discovery risk.
HYFT Prime™
Engineering and Design Engine
The AI engine built to support the path to IND. It refines candidates and enables de novo design, rigorously assessing liabilities and supporting risk-aware evaluation—providing the data needed to support regulatory development decisions.
Collaboration that drives discovery
Each program is unique. We create custom solutions as part of your team, combining deep scientific expertise and technical insight with open collaboration. Many clients describe MindWalk as their thought partner—driven to advance results to the clinic.
Where our research makes a broad impact
Oncology + Infectious Disease + Neurodegeneration + Metabolic Disease + Rare Disease + Inflammation + Market Kits
Let’s shape the future
One biointelligent ecosystem, explore partnership opportunities
Upcoming Events
Join us for ideas, conversations, and collaboration.
PMWC 2026
Silicon Valley USA
Mar 4-6, 2026
PEGS Boston
Boston USA
May 11-15, 2026
BioIT World
Boston USA
May 19-21, 2026
HubX Ab Tx - San Francisco
San Francisco USA
Sep 1, 2026
BioTechX Europe 2026
Basel, Switzerland
Oct 6-8, 2026